HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

PF-05230907

zymogen-like variant of recombinant activated coagulation factor X (FXa)

Also Known As:

FXa I16L

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Camire, Rodney M: 2 articles (01/2016 - 10/2011)
2.	Ivanciu, Lacramioara: 2 articles (01/2016 - 10/2011)
3.	Arkin, Steven: 1 article (01/2021)
4.	Cardinal, Matthew: 1 article (01/2021)
5.	Diringer, Michael N: 1 article (01/2021)
6.	Li, Gang: 1 article (01/2021)
7.	Lo, Benjamin: 1 article (01/2021)
8.	Masjuan, Jaime: 1 article (01/2021)
9.	Pérez de la Ossa, Natalia: 1 article (01/2021)
10.	Silva Blas, Yolanda: 1 article (01/2021)

Related Diseases

1.	Cerebral Hemorrhage 01/01/2021 - "This study aimed to determine the maximum tolerated dose and to evaluate the overall safety and tolerability of single doses of PF-05230907 in subjects with acute intracerebral hemorrhage. " 01/01/2021 - "Phase 1b Study to Evaluate Safety, Tolerability, and Maximum Tolerated Dose of PF-05230907 for Intracerebral Hemorrhage." 01/01/2021 - "Single doses of PF-05230907 appeared to be tolerated across a range of doses in the intracerebral hemorrhage population, with thrombotic events observed only at the highest dose level tested. "
2.	Hemorrhage 10/23/2011 - "Moreover, using human or murine analogs, we show that FXa(I16L) is more efficacious than FVIIa, which is used to treat bleeding in hemophilia inhibitor patients. " 10/23/2011 - "FXa(I16L) may provide an effective strategy to enhance blood clot formation and act as a rapid pan-hemostatic agent for the treatment of bleeding conditions." 01/01/2016 - "FXa(I16L) also reduces the anticoagulant-associated bleeding in vivo that is induced by the thrombin inhibitor dabigatran. "
3.	Hemophilia A (Haemophilia) 10/23/2011 - "Using mouse models of hemophilia, we show that FXa(I16L) has a longer half-life than wild-type FXa and does not cause excessive activation of coagulation. " 10/23/2011 - "Moreover, using human or murine analogs, we show that FXa(I16L) is more efficacious than FVIIa, which is used to treat bleeding in hemophilia inhibitor patients. " 09/01/2015 - "Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen-like FXa(I16L)."
4.	Vascular System Injuries 10/23/2011 - "Once clotting mechanisms are activated to produce its cofactor FVa, FXa(I16L) is driven to the protease state and restores hemostasis in hemophilic animals upon vascular injury. "
5.	Thrombosis (Thrombus) 10/23/2011 - "FXa(I16L) may provide an effective strategy to enhance blood clot formation and act as a rapid pan-hemostatic agent for the treatment of bleeding conditions."

Related Drugs and Biologics

1.	Thrombin
2.	Peptide Hydrolases (Proteases)
3.	Hemostatics (Antihemorrhagics)
4.	Enzyme Precursors (Zymogens)
5.	Anticoagulants
6.	Dabigatran